Tris Pharma has reported another Phase III win with its investigational pain therapy, cebranopadol, and it is now setting up a submission for approval to the US Food and Drug Administration (FDA).

MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today announced positive topline results from its ALLEVIATE-2 Phase 3 pivotal ...

Tris Pharma has reported positive topline outcomes from its ALLEVIATE-1 Phase III trial of cebranopadol for treating moderate-to-severe acute pain in individuals post-abdominoplasty surgery.

Tris Pharma has set its sights on an FDA filing for pipeline drug cebranopadol before the end of this year after the drug achieved significant pain relief in abdominoplasty patients in a late ...

Tris Pharma’s opioid alternative has scored a third win in a trio of clinical trials, providing the biotech with the data needed to take the pain relief drug to the FDA this year. The latest ...